The Medical Letter on Drugs and Therapeutics
Empagliflozin/Metformin (Synjardy) for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Synjardy (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin (Jardiance) and metformin (Glucophage, and others), for treatment of patients with type 2 diabetes not adequately controlled on either of these drugs alone or already being treated with both empagliflozin and metformin. It is the third SGLT2 inhibitor/metformin combination to be approved in the US.1

STANDARD TREATMENT — Used alone, oral antihyperglycemic drugs generally lower glycated hemoglobin (HbA1c) by 0.5-1.5%. Metformin is the preferred first-line treatment for type 2 diabetes, but most patients eventually require multi-drug therapy or insulin to achieve glycemic control.2 There is no consensus on which drug(s) should be added to metformin, which is ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Empagliflozin Metformin (Synjardy) for Type 2 Diabetes
Article code: 1484c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian